New injection aims to slow kidney damage in IgA nephropathy
NCT ID NCT07305974
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called RG002C0106 in 30 adults with IgA nephropathy, a kidney disease. The goal is to see if the drug safely reduces protein in urine, a sign of kidney damage. Participants receive either the drug or a placebo, and neither they nor their doctors know which they get.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY (IGAN) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University First Hospital
RECRUITINGBeijing, Beijing Municipality, 100034, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells tame autoimmune kidney disease?
- Can an Anti-Inflammatory diet protect the kidneys? a trial puts the autoimmune protocol to the test
- Atacicept's Long-Term promise for kidney disease
- Scientists investigate mysterious loin pain in kidney disease
- New hope for kidney patients: drug aims to prevent relapse
- 800-Patient study aims to uncover best treatments for kidney disease